title: [Medications in smoking cessation].
abstract: Physicians can aid their patients' smoking cessation by providing psychological support, advice, behavioral strategies, and drugs. Success depends on appropriate management, including selection of the right moment to begin treatment and an understanding of the development of the withdrawal syndrome, smoking urges, and the possibility of failure. The standard pharmacological treatment for nicotine dependence uses different forms of nicotine substitutes and bupropion, while we await data about other drugs currently under study. The score on the "simplified" Fagerström questionnaire usually determines the initial nicotine dose. Six forms of nicotine substitutes are available. They provide either prolonged nicotine release (transcutaneous patches) that prevents withdrawal symptoms, or rapid release through the buccal and nasal mucosa (chewing gum, suckers, inhalers and nasal sprays) to anticipate the positive effects represented by cigarettes and the urges occurring during withdrawal. The efficacy of these substitutes, widely studied, is approximately twice that of placebo. Their use is no longer contraindicated in patients with heart disease, when necessary. Bupropion should be used in treating nicotine dependence either as a first-line treatment, or if nicotine substitutes (150 mg/d the first week, 300 mg/d thereafter) fail. The combination of bupropion and nicotine substitutes can be considered, either from the outset for heavy or very heavy smokers, or afterwards, if withdrawal symptoms or urges to smoke persist in subjects treated by only one of these two drug classes. One of the new drugs under evaluation is rimonabant, the first representatives of a new class of drugs, selective CB1 endocannabinoid receptor antagonists. Promising results about its use in smoking cessation were released in 2004.
authors.affiliation: Département de cardiologie, CHU de Brest (29). jacques.mansourati@chu-brest.fr
authors.forename: J
authors.initials: J
authors.lastname: Mansourati
authors.forename: M-L
authors.initials: ML
authors.lastname: Borel
authors.forename: S
authors.initials: S
authors.lastname: Munier
authors.forename: A-L
authors.initials: AL
authors.lastname: Guevel-Jointret
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids / Q000037:antagonists & inhibitors; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002638:Chewing Gum; D002648:Child; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D011109:Polymethacrylic Acids / Q000008:administration & dosage*; D011145:Polyvinyls / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077285:Rimonabant; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology; D011795:Surveys and Questionnaires; D013997:Time Factors; D061485:Tobacco Use Cessation Devices
chemical_list: D018687:Antidepressive Agents, Second-Generation; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D000697:Central Nervous System Stimulants; D002638:Chewing Gum; D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D010880:Piperidines; D011109:Polymethacrylic Acids; D011145:Polyvinyls; D011720:Pyrazoles; D016642:Bupropion; D009538:Nicotine; D000077285:Rimonabant